Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  AUSTRALIAN SECURITIES EXCHANGE LIMITED  >  Cochlear Limited    COH   AU000000COH5

End-of-day quote. End-of-day quote  - 08/21
155.27 AUD   -1.42%
08/18 COCHLEAR : Appendix 3Y - Chris Smith
08/17 COCHLEAR : COH FY17 Result Announcement
08/17 COCHLEAR : COH Investor Handbook Aug17
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Cochlear Limited : COH Jury Trial Verdict on USA Patent Infringement Case

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/24/2014 | 03:51am CEST
ASX RELEASE 24th January 2014 COCHLEAR LIMITED: JURY TRIAL VERDICT ON USA PATENT INFRINGEMENT CASE

Cochlear Limited, Sydney, 24th January 2014 (ASX:COH) today announced that a jury verdict in the patent infringement lawsuit by the Alfred E. Mann Foundation for Scientific Research ("AMF") and Advanced Bionics LLC ("AB") has been reached.
A jury in the United States District Court in Los Angeles, California found direct, contributory and wilful, but not induced infringement against Cochlear Limited and its USA subsidiary Cochlear Americas and awarded damages of US$131.2 million against Cochlear.
No judgment has been entered based on the verdict as important issues still remain to be decided by the Judge. These decisions may negate some of the findings of the jury and could alter the damages awarded by the jury.
Cochlear believes the facts and the law do not support the jury's findings and will seek to overturn the verdict in post-trial motions with the District Court and, if necessary, through the appeals process.
This lawsuit was disclosed to ASX when it was filed in December 2007. The verdict relates to two (2) United States patents on testing systems and methods for a cochlear implant. The patents were exclusively licenced by AMF to AB which is a competitor to Cochlear.
One of the patents expired in September 2009 and the other expires in March 2014. As a result, the verdict and any following judgment entered against Cochlear will not disrupt Cochlear's business or customers in the United States.
As at the date of this announcement, Cochlear had not accrued any liability in its financial statements for this verdict. In addition, Cochlear has not yet determined the impact, if any, on its financial statements.
Cochlear's Chief Executive Officer and President Dr Chris Roberts said, "We strongly disagree with the jury verdict and will appeal any judgment entered against Cochlear by the Court".
Ends
Company contacts:
Dr Chris Roberts, CEO/President p: + 61 2 9428 6555
Neville Mitchell, CFO
p: + 61 2 9428 6555

Page 1 of 1

distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on COCHLEAR LIMITED
08/18 COCHLEAR : Appendix 3Y - Chris Smith
08/17 COCHLEAR : Patent Issued for Power and Data Transfer in Hearing Prostheses (USPT..
08/17 COCHLEAR : COH FY17 Result Announcement
08/17 COCHLEAR : COH Investor Handbook Aug17
08/17 COCHLEAR : COH FY17 Result Presentation Slides
08/17 COCHLEAR : COH 2017 Annual Report
08/17 COCHLEAR : Dividend/Distribution - COH
08/17 COCHLEAR : COH 2017 Tax Contribution Report
08/17 COCHLEAR : COH 2017 Corporate Governance Statement
08/03 COCHLEAR : Patent Issued for Sound Processing in a Hearing Device Using External..
More news
News from SeekingAlpha
07/26 Apple and Cochlear announce Sound Processor for hearing implant
07/16 WEEK IN REVIEW : BGI Genomics Completes $81-Million Chi-Next IPO
2016 How Do I Manage A Favorite Holding That's Now Overvalued?
2016 Smaller Medtechs In Charge Of Their Own Destiny
2016 The Psychology Of Investing
Financials ( AUD)
Sales 2018 1 364 M
EBIT 2018 350 M
Net income 2018 247 M
Debt 2018 46,7 M
Yield 2018 1,94%
P/E ratio 2018 36,46
P/E ratio 2019 31,58
EV / Sales 2018 6,67x
EV / Sales 2019 6,04x
Capitalization 9 045 M
Chart COCHLEAR LIMITED
Duration : Period :
Cochlear Limited Technical Analysis Chart | COH | AU000000COH5 | 4-Traders
Technical analysis trends COCHLEAR LIMITED
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 11
Average target price 141  AUD
Spread / Average Target -10%
EPS Revisions
Managers
NameTitle
Christopher M. Smith Chief Executive Officer & Director
Dig Howitt President
Roderick Holliday-Smith Chairman
Brent Cubis Chief Financial Officer
James F. Patrick Chief Scientist & Senior Vice President
Sector and Competitors
1st jan.Capitalization (M$)
COCHLEAR LIMITED28.52%7 169
SONOVA HOLDING29.98%10 876
STRAUMANN HOLDING47.67%9 660
INSULET CORPORATION45.49%3 183
MODERN DENTAL GROUP LTD0.00%369
REWALK ROBOTICS LTD-51.79%29